Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
COMBINATION COMPRISING AN IL-4R ANTAGONIST, A CORTICOSTEROID AND A LONG-ACTING BETA2-ADRENERGIC AGONIST FOR TREATING ASTHMA
No-Receipt date
2024-01386 - 09/04/2024
No-Filing date
20240400870 - 09/04/2024
No-Granting date
3115158 - 29/04/2024
No-EPO application date
21191120.1 - 20/02/2015
No-EPO granting date
3973987 - 10/01/2024
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
4/2024 - 16/05/2024
Expiration date
21/02/2035
Kind of title
Validation of European Patent
Legal status
VALID
Priorities
US201461943019 P21/02/2014/US
EP1430641315/09/2014/EP
US201462077669 P10/11/2014/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61P 11/06
A61K 39/395
A61K 31/56
A61K 31/167
A61K 31/00
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1600805
SANOFI BIOTECHNOLOGY
82 AVENUE RASPAIL
94250 GENTILLY
FRANCE
1600806
REGENERON PHARMACEUTICALS, INC.
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591-6707
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
4168887
PIROZZI, GIANLUCA
4168888
SKOBIERANDA, FRANCK
4168889
LI, YONGTAO
4168890
GRAHAM, NEIL
4168891
WEINSTEIN, STEVEN P.
Representatives
Code
Firstname
Surname
Address
Town
Zip
3614
AIKATERINI
SIOTOU "KATERINA SIOTOU KAI SYNERGATES DIKIGORIKI ETAIREIA"
PATISION (28IS OKTOVRIOU) 122
ATHINA (ATTIKIS)
11257
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
4766
AIKATERINI
SIOTOU
PATISION (28IS OKTOVRIOU) 122
ATHINA (ATTIKIS)
11257
GREECE
Owners History
Title Instruments
Payments history
11 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).